INTRODUCTION AND OBJECTIVE: Continuous follow-up after the treatment of non-muscle invasive bladder cancer (NMIBC) is mandatory for early recurrence detection. This study investigates the clinical relevance of new diagnostic tools such as an mRNA-based urine test (XpertÓ Bladder Cancer Monitor, Cepheid, USA) and Narrow Band ImagingÓ (NBI, Olympus) and compares them to the established follow-up methods.METHODS: This was a prospective single-center study involving patients undergoing NMIBC screening with enrollment from January 2018 to March 2020; the follow-up concluded in January 2021. Aside from performing the standard of care, including conventional white light cystoscopy (WLC), cytology, and sonography, patients also submitted urine for the XPERTÓ urine test and underwent NBI cystoscopy. These latter two tests were compared against WLC and the anatomic pathology in cases of NMIBC recurrence. Follow-up data were included in cases in which (a) WLC findings were ambiguous and pathology was postponed, or (b) in instances where XPERTÓ yielded a positive result while WLC was negative. According to the manufacturer, the XPERTÓ cut-off value (COV) for a positive result was set at a linear discriminant analysis (LDA) value of 0.5. The sensitivity (SE), specificity (SP), positive an negative predictive values (PPV, NPV) and median LDA values for tumor negative and tumor positive low-(LG) and highgrade (HG) lesions were calculated. SE and SP for different XPERTÓ LDA thresholds were also calculated.RESULTS: 301 patients were enrolled during the study period. 49 patients demonstrated NMIBC disease recurrence. In this subset, NBI cystoscopy was congruent with WLC in all patients. Cytology harbored an SE and SP of 27% and 97% (PPV: 65%; NPV 0.87%), respectively, whereas with XPERTÓ, the SE and SP were 58% and 89% (PPV: 51%; NPV: 92%; AUC: 0.79 (0.76-0.871)). Assessment of higher XPERTÓ LDA thresholds elicited higher SE and accordingly lower SP (for e.g., when the LDA was raised to 0.76, the SE was 98% and SP was 40%; when LDA was further raised to 1.0, the SE was 99% while SP was 23%). The overall median LDA values in a tumor negative setting was 0.33 (0.17 e 0.45); in an overall tumor positive bladder, the median LDA was 0.56 (0.35 e 0.95), while LG disease exhibited an LDA of 0.38 (0.26 e 0.52) and HG disease was 0.85 (0.51 e 1.06) (p < 0.001). A subgroup analysis revealed better SE but similar SP (PPV, NPV) for HG compared to LG recurrence, where SE was 74% and SP of 89% (39%, 97%) vs. SE of 33%, and SP of 89% (21%, 94%).CONCLUSIONS: NBI cystoscopy does not necessarily offer any additional benefit to standard WLC, and WLC remains the gold standard for visualization in NMIBC surveillance. Yet, the XPERTÓ Bladder Cancer Monitoring platform may confer better sensitivity and a diagnostic advantage in high grade, but not low grade, disease recurrence.
Background Severe functional impairment is often considered a contraindication to intravesical therapy for nonmuscle-invasive bladder cancer (NMIBC). A tailored intravesical bacillus Calmette-Guérin (BCG) procedure was evaluated in high-risk (HR)-NMIBC patients with severe functional impairment. Materials and methods Patients with a Katz Index score of 2 or less and an initial diagnosis of HR-NMIBC with atraumatic insertion of a Foley-type indwelling catheter, bladder emptying, and BCG instillation were prospectively treated; after 2 hours, the bladder was emptied and the catheter was removed (group A). After propensity score matching, 52 patients in group A were compared with that of 52 consecutive patients in group B using a retrospective database, with similar baseline/oncological characteristics and treated with standard intermittent catheterization. Moreover, groups A and B were compared with that of 130 consecutive patients (group C) retrospectively evaluated, with similar oncological characteristics but with a Katz Index score of 3 or greater and treated with standard intermittent catheterization. Results The discontinuation rates were 11.5%, 35%, and 9% in groups A, B, and C, respectively (A vs. B, log-rank score 42.52 [ p < 0.05]; B vs. C, 107.6 [ p < 0.05]; A vs. C, 3.45 [ p > 0.05]). The overall adverse event rates were 38.5%, 57.7%, and 39.2%, respectively (A vs. B, p = 0.04; B vs. C, 0.03; A vs. C, 0.92). The rates of severe adverse events were 1.9%, 1.9%, and 1.5%, respectively, without statistically significant differences. The cumulative HR disease-free survival rates were 63.4%, 48%, and 69.2%, respectively (A vs. B, log-rank score 154.9 [ p < 0.05]; B vs. C, 415 [ p < 0.05]; A vs. C, 244 [ p < 0.05]). Conclusions A tailored intravesical instillation procedure may reduce BCG discontinuation and adverse effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.